Approach to Klebsiella pneumoniae UTI

Initial Assessment and Classification

The European Urology guidelines recommend determining if the UTI is complicated or uncomplicated, as this fundamentally changes management, with Klebsiella spp. being among the most common pathogens in complicated UTIs alongside E. coli, Proteus, Pseudomonas, Serratia, and Enterococcus 1, 2
Male gender is considered a factor defining complicated UTI, as all male UTIs are considered complicated 3
Other factors defining complicated UTI include urinary tract obstruction, foreign bodies, incomplete bladder voiding, diabetes mellitus, immunosuppression, recent instrumentation, and healthcare-associated infection 1, 2

The European Urology guidelines recommend always obtaining urine culture and susceptibility testing before initiating therapy, as this is mandatory for all Klebsiella UTIs given the higher likelihood of antimicrobial resistance compared to E. coli 1, 2, 3
Blood cultures should be obtained in patients requiring hospitalization or with signs of systemic infection 4

For uncomplicated cystitis, first-line oral options include ciprofloxacin 500-750 mg twice daily for 7 days or levofloxacin 750 mg once daily for 5 days, if local fluoroquinolone resistance is <10% 1, 4
For uncomplicated pyelonephritis, preferred oral regimens include ciprofloxacin 500-750 mg twice daily for 7 days or levofloxacin 750 mg once daily for 5 days, if local resistance <10% 1, 4
For complicated UTI, empiric parenteral therapy should be based on severity and risk factors, with options including fluoroquinolones, extended-spectrum cephalosporins, piperacillin-tazobactam, and aminoglycosides with or without ampicillin 1, 2, 3

The European Urology guidelines recommend not using fluoroquinolones empirically if local resistance rates exceed 10%, the patient has used fluoroquinolones in the last 6 months, or the patient has risk factors for ESBL-producing organisms 1, 3, 4

Once culture results return, therapy should be narrowed to the most appropriate agent based on susceptibilities, as part of antimicrobial stewardship principles 1, 2
Therapy should be switched from IV to oral when the patient is clinically stable, afebrile for 24-48 hours, and able to tolerate oral intake 1, 2

Antimicrobial therapy will fail without addressing complicating factors, including removing or replacing urinary catheters, relieving urinary obstruction, optimizing diabetes control, and addressing incomplete bladder emptying 1, 2, 3